Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. UNCY
UNCY logo

UNCY

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

UNCY News

Unicycive's Drug Application Accepted by FDA with Target Date Set

Jan 29 2026Newsfilter

Unicycive's Kidney Disease Therapy NDA Accepted by FDA

Jan 29 2026seekingalpha

Unicycive's Drug Application Accepted by FDA

Jan 29 2026Newsfilter

Unicycive Resubmits NDA for OLC to Treat Hyperphosphatemia in CKD Patients

Dec 29 2025NASDAQ.COM

Unicycive Resubmits OLC NDA to FDA, Cash Runway Until 2027

Dec 29 2025Globenewswire

Unicycive Resubmits OLC NDA to FDA, Cash Runway Until 2027

Dec 29 2025Newsfilter

Quantum Corp Faces Investigation Over Financial Misstatements

Dec 18 2025Globenewswire

Five Below (FIVE) Class Action Survives Dismissal Motion Amid Securities Fraud Allegations

Dec 03 2025Globenewswire

Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements

Dec 02 2025Globenewswire

Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

Dec 02 2025NASDAQ.COM

Crucial Update for Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR), Five Below, Inc. (NASDAQ: FIVE), Maison Solutions Inc. (NASDAQ: MSS), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You

Nov 14 2025Globenewswire

Bragar Eagel & Squire Launches Investigation into Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus for Long-Term Stockholders; Invites Investors to Reach Out to the Firm

Nov 13 2025Globenewswire

Unicycive Therapeutics Reports GAAP EPS of -$0.46, Exceeding Estimates by $0.07

Nov 12 2025SeekingAlpha

Crucial Update for Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR), Five Below, Inc. (NASDAQ: FIVE), Molina Healthcare, Inc. (NYSE: MOH), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You

Nov 10 2025Globenewswire

UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. Investigates Unicycive Therapeutics, Inc. for Long-Term Stockholders and Urges Investors to Reach Out to the Firm

Oct 31 2025Globenewswire

Unicycive Therapeutics to Present New Data Highlighting the Promise of Oxylanthanum Carbonate for Hyperphosphatemia Treatment at the 2025 American Society of Nephrology Kidney Week Conference

Oct 30 2025Newsfilter